The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.

Toshiharu Nagatsu, Akira Nakashima, Hirohisa Watanabe, Shosuke Ito, Kazumasa Wakamatsu, Fabio A Zucca, Luigi Zecca, Moussa Youdim, Maximilian Wulf, Peter Riederer, Johannes M Dijkstra

Journal: Journal of neural transmission (Vienna, Austria : 1996) 2023;130(5):611-625

PMID: 36939908

Abstract

The dark pigment neuromelanin (NM) is abundant in cell bodies of dopamine (DA) neurons in the substantia nigra (SN) and norepinephrine (NE) neurons in the locus coeruleus (LC) in the human brain. During the progression of Parkinson's disease (PD), together with the degeneration of the respective catecholamine (CA) neurons, the NM levels in the SN and LC markedly decrease. However, questions remain among others on how NM is associated with PD and how it is synthesized. The biosynthesis pathway of NM in the human brain has been controversial because the presence of tyrosinase in CA neurons in the SN and LC has been elusive. We propose the following NM synthesis pathway in these CA neurons: (1) Tyrosine is converted by tyrosine hydroxylase (TH) to L-3,4-dihydroxyphenylalanine (L-DOPA), which is converted by aromatic L-amino acid decarboxylase to DA, which in LC neurons is converted by dopamine β-hydroxylase to NE; (2) DA or NE is autoxidized to dopamine quinone (DAQ) or norepinephrine quinone (NEQ); and (3) DAQ or NEQ is converted to eumelanic NM (euNM) and pheomelanic NM (pheoNM) in the absence and presence of cysteine, respectively. This process involves proteins as cysteine source and iron. We also discuss whether the NM amounts per neuromelanin-positive (NM) CA neuron are higher in PD brain, whether NM quantitatively correlates with neurodegeneration, and whether an active lifestyle may reduce NM formation.

© 2023. The Author(s).

Address: Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan. [email protected].; Department of Physiological Chemistry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.; Department of Neurology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.; Institute for Melanin Chemistry, Fujita Health University, Toyoake, Aichi, Japan.; Institute of Biomedical Technologies, National Research Council of Italy, Segrate (Milan), Italy.; Technion-Rappaport Family Faculty of Medicine, Haifa, Israel.; Department of Biology, Yonsey World Central University, Seoul, South Korea.; Medical Proteome-Analysis, Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.; Medizinisches Proteom‑Center, Medical Faculty, Ruhr-University Bochum, Bochum, Germany.; Clinic and Polyclinic of Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Würzburg, Germany.; Department and Research Unit of Psychiatry, Syddansk University, Odense, Denmark.; Center for Medical Science, Fujita Health University, Toyoake, Aichi, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.